Amarin Corp. PLC ADR (AMRN) News
Filter AMRN News Items
AMRN News Results
|Loading, please wait...|
AMRN News Highlights
- For AMRN, its 30 day story count is now at 3.
- Over the past 26 days, the trend for AMRN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- FOLD are the most mentioned tickers in articles about AMRN.
Latest AMRN News From Around the Web
Below are the latest news stories about AMARIN CORP PLC that investors may wish to consider to help them evaluate AMRN as an investment opportunity.
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amarin (AMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
-- Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo -- -- Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease -- -- Findings Continue to Reinforce the Scientific Data and Clinical Use of VASCEPA®/VAZKEPA® to Reduce Cardiovascular Risk -- -- Results Presented Today at the American Heart Association (AHA) Scientific Sessions 2023 and Simultaneously Published in the European Heart Journal Open -- DUBLIN, Ireland
Amarin Corporation plc (NASDAQ:AMRN) Q3 2023 Earnings Call Transcript November 1, 2023 Amarin Corporation plc misses on earnings expectations. Reported EPS is $-0.05 EPS, expectations were $-0.02. Operator: Welcome to Amarin Corporation’s conference call to discuss its third quarter 2023 financial results and business updates. I would now like to turn the conference call over […]
Key Insights The projected fair value for Amarin is US$0.95 based on 2 Stage Free Cash Flow to Equity Amarin is...
Welcome to Amarin Corporation's conference call to discuss its third-quarter 2023 financial results and business updates. Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided under Federal Securities law.
Amarin's (AMRN) third-quarter 2023 earnings and revenues beat estimates. Vascepa sales in the United States decline year over year.
While the top- and bottom-line numbers for Amarin (AMRN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Company maintains positive cash flow for fifth consecutive quarter
-- Company Reported Total Net Revenues of $66 Million in the Third Quarter 2023 -- -- Delivered Positive Cash Flow of $8 Million in the Quarter, Marking Fifth Consecutive Quarter of Cash Positive Operations1; Quarter-Ending Cash Position of $321 Million -- -- Company Continues to Deliver Significant U.S. Profit Through Extended Lifecycle and Market Leadership of Branded VASCEPA® -- -- Early Launch Progress in European Countries Driven by New Leadership -- -- Company to Host Conference Call Today